All Updates

All Updates

icon
Filter
M&A
Context Therapeutics acquires CT-95 for solid tumor treatment from Link Immunotherapeutics
Precision Medicine
Jul 10, 2024
This week:
Partnerships
Qualcomm and Google partner to develop AI-driven automotive solutions
Auto Tech
Yesterday
Product updates
Meta AI releases LayerSkip to accelerate inference in LLMs
Generative AI Infrastructure
Yesterday
Funding
Freeform secures funding from NVIDIA's NVentures
Additive Manufacturing
Oct 22, 2024
Product updates
Flexxbotics announces compatibility with LMI Technologies for quality inspection
Smart Factory
Oct 22, 2024
Funding
Oxla raises USD 11 million in seed funding to drive commercialization
Data Infrastructure & Analytics
Oct 22, 2024
Product updates
Cohesity enhances Gaia, its AI assistant, with visual data exploration and expanded data sources
Data Infrastructure & Analytics
Oct 22, 2024
Product updates
Finzly launches FedNow service through BankOS platform in AWS marketplace
FinTech Infrastructure
Oct 22, 2024
Product updates
Runway launches Act-One for AI facial expression motion capture
Generative AI Applications
Oct 22, 2024
Product updates
Ideogram launches Canvas for image manipulation and generation
Generative AI Applications
Oct 22, 2024
Partnerships
UiPath partners with Inflection AI to integrate AI solutions for enterprises
Generative AI Applications
Oct 22, 2024
Precision Medicine

Precision Medicine

Jul 10, 2024

Context Therapeutics acquires CT-95 for solid tumor treatment from Link Immunotherapeutics

M&A

  • Context Therapeutics has acquired CT-95, a bispecific antibody drug previously owned by Link Immunotherapeutics, for an undisclosed amount.

  • CT-95, now added to Context Therapeutics' portfolio, is a potentially first-in-class mesothelin x CD3 T cell-engaging bispecific antibody. It has received Investigational New Drug (IND) clearance from the FDA and is claimed to have high potential in treating several underserved solid cancers, including ovarian, lung, and pancreatic. Following the acquisition, Context Therapeutics plans to begin clinical trials for the drug, which, along with the acquisition, are planned to be funded using its existing cash reserves.

  • Context Therapeutics is a biopharmaceutical company that develops novel treatments for solid tumors. The company's primary focus is on CTIM-76, a selective Claudin 6 (CLDN6) x CD3 bispecific antibody designed to target CLDN6-positive tumors. Such tumors include ovarian, endometrial, testicular, and lung cancers, where CLDN6 is present in high concentrations but is minimally expressed in healthy adult tissues​. The company aims to advance CTIM-76 through to clinical development, with a Phase I clinical trial expected to begin in mid-2024.

Contact us

Gain access to all industry hubs, market maps, research tools, and more
Get a demo
arrow
menuarrow

By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.